Curium, a global leader in nuclear medicine, has completed the acquisition of Nucleis, a company specializing in the GMP manufacturing and distribution of PET radiopharmaceuticals. This acquisition aims to enhance Curium's PET manufacturing capacity across its 32 sites in Western Europe, improve the reliability and accessibility of PET diagnostics, and expand its CDMO capabilities for developing innovative PET tracers in oncology, neurology, and cardiology. The move is expected to reinforce Curium's supply chain and accelerate the availability of life-saving diagnostics for patients in the Benelux region and Germany. Curium's CEO expressed enthusiasm about integrating Nucleis into their operations, which will lead to better healthcare solutions.
Thu, 10 Apr 2025 09:22:34 GMT | The Manila Times